CY1122612T1 - Μεθοδος - Google Patents

Μεθοδος

Info

Publication number
CY1122612T1
CY1122612T1 CY20191101058T CY191101058T CY1122612T1 CY 1122612 T1 CY1122612 T1 CY 1122612T1 CY 20191101058 T CY20191101058 T CY 20191101058T CY 191101058 T CY191101058 T CY 191101058T CY 1122612 T1 CY1122612 T1 CY 1122612T1
Authority
CY
Cyprus
Prior art keywords
cell population
express
population
therapeutic
cells
Prior art date
Application number
CY20191101058T
Other languages
English (en)
Inventor
Luigi Naldini
Bernhard Rudolf Gentner
Erika ZONARI
Original Assignee
Ospedale San Raffaele S.R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201318830A external-priority patent/GB201318830D0/en
Priority claimed from GB201409067A external-priority patent/GB201409067D0/en
Application filed by Ospedale San Raffaele S.R.L. filed Critical Ospedale San Raffaele S.R.L.
Publication of CY1122612T1 publication Critical patent/CY1122612T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof

Abstract

Μια μέθοδος παρασκευής ενός θεραπευτικού κυτταρικού πληθυσμού για κλινική χρήση από έναν αρχικό κυτταρικό πληθυσμό που περιλαμβάνει αρχέγονα αιμοποιητικά κύτταρα, με την εν λόγω μέθοδο να περιλαμβάνει το διαχωρισμό ενός πληθυσμού κυττάρων που ουσιαστικά δεν εκφράζουν το CD38 αλλά τα οποία εκφράζουν το CD34 από τον αρχικό πληθυσμό κυττάρων, και τη μεταγωγή του διαχωρισμένου κυτταρικού πληθυσμού με έναν φορέα για να ληφθεί ο θεραπευτικός κυτταρικός πληθυσμός.
CY20191101058T 2013-10-24 2019-10-09 Μεθοδος CY1122612T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201318830A GB201318830D0 (en) 2013-10-24 2013-10-24 Method
GB201409067A GB201409067D0 (en) 2014-05-21 2014-05-21 Method
PCT/IB2014/065594 WO2015059674A1 (en) 2013-10-24 2014-10-24 Method

Publications (1)

Publication Number Publication Date
CY1122612T1 true CY1122612T1 (el) 2021-03-12

Family

ID=52007237

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191101058T CY1122612T1 (el) 2013-10-24 2019-10-09 Μεθοδος

Country Status (11)

Country Link
US (2) US10617721B2 (el)
EP (2) EP3613859A1 (el)
JP (2) JP6691048B2 (el)
KR (1) KR20160075676A (el)
CN (1) CN106062201B (el)
AU (1) AU2014338555B2 (el)
CA (1) CA2927712A1 (el)
CY (1) CY1122612T1 (el)
ES (1) ES2747951T3 (el)
SG (1) SG11201603166UA (el)
WO (1) WO2015059674A1 (el)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102011532B1 (ko) * 2011-09-30 2019-08-16 블루버드 바이오, 인코포레이티드. 개선된 바이러스 형질도입을 위한 화합물
GB201407322D0 (en) * 2014-04-25 2014-06-11 Ospedale San Raffaele Gene therapy
US11326183B2 (en) 2016-02-12 2022-05-10 Bluebird Bio, Inc. VCN enhancer compositions and methods of using the same
CA3040687A1 (en) 2016-10-14 2018-04-19 Childrens' Medical Center Corporation Compositions and methods for treating diseases and disorders of the central nervous system
WO2018106610A1 (en) * 2016-12-05 2018-06-14 The Regents Of The University Of California Immunomagnetic bead-based method to enrich stem cells from whole hematopoietic tissue
CA3050691A1 (en) 2017-01-17 2018-07-26 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating lysosomal storage diseases and disorders
GB201706394D0 (en) 2017-04-21 2017-06-07 Ospedale San Raffaele Srl Gene Therapy
US20210115453A1 (en) * 2017-08-31 2021-04-22 Poseida Therapeutics, Inc. Transposon system and methods of use
FR3074189A1 (fr) * 2017-11-30 2019-05-31 Assistance Publique - Hopitaux De Paris Methode de generation de greffons de cellules souches hematopoietiques
WO2021067613A1 (en) * 2019-10-01 2021-04-08 Children's Medical Center Corporation Compositions and methods for treating amyotrophic lateral sclerosis
EP4146797A1 (en) 2020-05-06 2023-03-15 Orchard Therapeutics (Europe) Limited Treatment for neurodegenerative diseases

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5840580A (en) 1990-05-01 1998-11-24 Becton Dickinson And Company Phenotypic characterization of the hematopoietic stem cell
US5622853A (en) 1990-05-01 1997-04-22 Becton Dickinson And Company T lymphocyte precursor
AU4402193A (en) 1992-06-08 1994-01-04 Becton Dickinson & Company Human primitive stem cells
ES2157227T3 (es) 1993-02-09 2001-08-16 Becton Dickinson Co Asignacion automatica del linaje de leucemias agudas mediante citometria de flujo.
US6555324B1 (en) 1993-11-04 2003-04-29 Becton Dickinson & Company Method to distinguish hematopoietic progenitor cells
EP0662512A3 (en) 1993-12-20 1997-01-15 Becton Dickinson Co Human hematopoietic stem cells.
DE69531432T2 (de) 1994-09-23 2004-07-29 Becton Dickinson And Co. Verfahren zur Unterscheidung von granulomoncytischen Progenitoren in einer Population von CD34+ Zellen
US5723315A (en) 1996-08-23 1998-03-03 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
DK0968182T3 (da) 1996-08-07 2004-08-16 Darwin Discovery Ltd Hydroxam- og carboxylsyrederivater med MMP- og TNF-inhiberende aktivitet
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
EP0931138A4 (en) * 1996-10-10 2003-04-09 Univ Duke PROCESS FOR PRODUCING A THERMAL MICRO-ENVIRONMENT PROMOTING THE DEVELOPMENT OF DENDRITIC CELLS
WO1998017815A1 (en) 1996-10-17 1998-04-30 Oxford Biomedica (Uk) Limited Retroviral vectors
CA2219869A1 (en) 1997-10-31 1999-04-30 Hsc Research And Development Limited Partnership Human cd-34 hematopoietic stem cells
US6006633A (en) 1998-07-08 1999-12-28 The Stanley Works Pliers (1)
EP1135465A2 (en) 1998-12-04 2001-09-26 Naval Medical Research Center Human brain endothelial cells and growth medium and method for expansion of primitive cd34+cd38- bone marrow stem cells
WO2000034495A2 (en) 1998-12-04 2000-06-15 City Of Hope A method of genetically modifying very primitive quiescent human hematopoietic stem cells
CN102703379B (zh) 1999-01-19 2015-06-03 查珀尔希尔北卡罗来纳大学 人肝脏祖先
EP1224314B1 (en) * 1999-10-12 2007-01-17 Institut Pasteur Lentiviral triplex dna, and vectors and recombinant cells containing lentiviral triplex dna
US20020159984A1 (en) 1999-11-12 2002-10-31 Quality Biological, Inc. Cultivation of cells for long term engraftment
AU2001240078A1 (en) * 2000-03-07 2001-09-17 St. Jude Children's Research Hospital Highly efficient gene transfer into human repopulating stem cells by rd114 pseudotyped retroviral vector particles
US6849454B2 (en) 2000-03-07 2005-02-01 St. Jude Children's Research Hospital Highly efficient gene transfer into human repopulating stem cells by RD114 pseudotyped retroviral vector particles
GB0009760D0 (en) 2000-04-19 2000-06-07 Oxford Biomedica Ltd Method
NL1017973C2 (nl) 2000-05-10 2002-11-08 Tristem Trading Cyprus Ltd Inrichting.
US20040023324A1 (en) 2000-08-25 2004-02-05 Seiji Sakano Stem cell culture medium and culture method by using the same
EP2316919B1 (en) * 2001-02-14 2015-10-07 Anthrogenesis Corporation Post-partum mammalian placenta, its use and placental stem cells therefrom
AU2002360674A1 (en) * 2001-12-21 2003-07-30 The United States Of America Represented By The Secretary Of The U.S. Department Of The Navy In increasing gene transfer efficiency by pre-incubation with endothelial cells
IL152904A0 (en) 2002-01-24 2003-06-24 Gamida Cell Ltd Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
EP1482787A4 (en) * 2002-02-13 2006-02-15 Anthrogenesis Corp EMBRYONIC TYPE DERIVED STEM CELLS DERIVED FROM MAMMALIAN POST-PARTUM PLACENTA, USES THEREOF, AND METHODS OF TREATMENT BASED ON CELLS OF THIS TYPE
WO2004072264A2 (en) * 2003-02-12 2004-08-26 Johns Hopkins University School Of Medicine Fate determination by hes 1 in hematopoietic stem-progenitor cells and uses thereof
WO2004071464A2 (en) 2003-02-12 2004-08-26 Johns Hopkins University School Of Medicine Diagnostic application of differentially-expressed genes in lympho-hematopoietic stem cells
JP2007521831A (ja) 2004-02-11 2007-08-09 アルダジェン， インコーポレイテッド 幹細胞集団および使用方法
KR100561079B1 (ko) 2004-03-09 2006-03-15 재단법인서울대학교산학협력재단 자궁내막세포를 이용한 조혈모세포 또는 전구세포의 배양 및 증식 방법
EP1593737B1 (en) 2004-05-05 2011-02-02 Zorica Becker-Kojic Use of ACA glycoprotein antibodies for obtaining/maintaining pluripotent non-embryonic stem cells
US20060046268A1 (en) 2004-08-26 2006-03-02 Australian Stem Cell Centre Ltd. Diagnosis of anemia and optimizing treatment for heart repair
WO2006007539A1 (en) 2004-07-01 2006-01-19 Virxsys Corporation Vector packaging cell line
JP4706208B2 (ja) 2004-08-27 2011-06-22 株式会社アイル 造血幹細胞の製造方法
MX2007008869A (es) 2005-01-27 2007-09-11 Regenetech Inc Metodo para proporcionar material celular facilmente disponible derivado de sangre de cordon, y una composicion de la misma.
EP1853110A4 (en) 2005-02-28 2009-01-14 Regenetech Inc PROCESS FOR THE PRODUCTION OF AN EASILY AVAILABLE CELLULAR SUBSTANCE DERIVED FROM PERIPHERAL BLOOD AND COMPOSITION THEREOF
EP1853282A4 (en) 2005-02-28 2010-04-28 Regenetech Inc METHOD AND COMPOSITION FOR REPAIRING EPITHELIAL CELLS OR OTHER CELLS AND FABRICS
KR20070111533A (ko) 2005-02-28 2007-11-21 리제네텍 인코포레이티드 당뇨병 치료용 조성물 및 방법
EP1853301A2 (en) 2005-02-28 2007-11-14 Regenetech, Inc. Method and composition for repairing heart tissue
FR2891551A1 (fr) 2005-10-03 2007-04-06 Jaafari Assia El Procede technique de preparation de cellules dentritiques a partir de progeniteurs hematopoietiques en deux etapes sans purification ou enrichissement prealable en cellules souches hematopoietiques.
KR100702862B1 (ko) 2005-12-01 2007-04-03 메디포스트(주) 제대혈 유래 간엽줄기세포를 세포영양막으로 이용한조혈모세포/전구세포의 체외 성장 및 증식방법
GB0526211D0 (en) 2005-12-22 2006-02-01 Oxford Biomedica Ltd Viral vectors
KR100773253B1 (ko) 2007-03-26 2007-11-05 주식회사 알앤엘바이오 성체줄기세포와의 공동배양을 통한 조혈모세포의 배양 및증식방법
WO2008136656A1 (en) * 2007-05-02 2008-11-13 Erasmus University Medical Center Rotterdam Improved methods and means for lentiviral gene delivery
WO2008136670A2 (en) 2007-05-02 2008-11-13 Erasmus University Medical Center Rotterdam Improved methods and means for lentiviral gene delivery
US9527828B2 (en) 2007-12-06 2016-12-27 Nissan Chemical Industries, Ltd. Method for expanding hematopoietic stem cells using heterocyclic compound
US20090191164A1 (en) 2008-01-15 2009-07-30 Ravindra Majeti Human hematopoietic multipotent progenitor cells
PE20100362A1 (es) * 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
AR071353A1 (es) 2009-02-20 2010-06-16 Regenetech Inc Metodo y composicion para reparar tejido cardiaco
EP2417984B1 (en) 2009-04-10 2016-03-30 Kyowa Hakko Kirin Co., Ltd. Method for treatment of blood tumor using anti-tim-3 antibody
ES2786039T3 (es) 2009-04-30 2020-10-08 Ospedale San Raffaele Srl Vector génico
CN101831434B (zh) 2009-07-27 2012-05-09 浙江大学 抗人cd45ra鼠免疫球蛋白可变区基因及用途
CN101706507B (zh) 2009-07-27 2013-05-01 浙江大学 用异硫氰酸荧光素标记的抗人cd45ra单抗的应用
CN101735979B (zh) 2009-12-31 2014-04-30 浙江中赢控股集团有限公司 体外扩增造血干细胞和前体细胞的方法
KR20120006386A (ko) 2010-07-12 2012-01-18 (주)마리아 바이오텍 1기 태반조직 유래 줄기세포 및 이를 함유하는 세포치료제
WO2012033352A2 (ko) 2010-09-08 2012-03-15 주식회사 강스템홀딩스 말과동물 양수 유래 다분화능 줄기세포 및 그 제조방법
WO2012094193A2 (en) 2011-01-03 2012-07-12 Bluebird Bio, Inc. Methods for enhancing the delivery of gene-transduced cells
CN102220282A (zh) 2011-04-26 2011-10-19 广东省人民医院 从白血病细胞株分选白血病干细胞的方法
KR20130028294A (ko) 2011-09-09 2013-03-19 주식회사 강스템홀딩스 개과 동물의 와튼 젤리-유래 중간엽 줄기세포의 분리 및 특성화
US9012215B2 (en) 2011-09-22 2015-04-21 The Johns Hopkins University Methods for identifying leukemia stem cells and distinguishing them from normal hematopietic stem cells in patients with acute myeloid leukemia: uses in diagnosis, treatment, and research
KR102011532B1 (ko) * 2011-09-30 2019-08-16 블루버드 바이오, 인코포레이티드. 개선된 바이러스 형질도입을 위한 화합물
KR101906156B1 (ko) 2011-11-22 2018-10-12 주식회사 강스템바이오텍 말과동물 양막-유래 중간엽 줄기세포
WO2013085303A1 (ko) 2011-12-06 2013-06-13 주식회사 강스템홀딩스 개과동물 양막-유래 다분화능 줄기세포
CN103018463B (zh) 2012-12-20 2015-08-05 北京大学人民医院 检测急性b淋巴细胞白血病相关免疫表型的试剂盒及其应用

Also Published As

Publication number Publication date
KR20160075676A (ko) 2016-06-29
US20160256492A1 (en) 2016-09-08
AU2014338555B2 (en) 2019-10-10
JP2016539659A (ja) 2016-12-22
WO2015059674A1 (en) 2015-04-30
ES2747951T3 (es) 2020-03-12
CN106062201A (zh) 2016-10-26
EP3060670A1 (en) 2016-08-31
EP3613859A1 (en) 2020-02-26
JP6691048B2 (ja) 2020-04-28
SG11201603166UA (en) 2016-05-30
US10617721B2 (en) 2020-04-14
CA2927712A1 (en) 2015-04-30
EP3060670B1 (en) 2019-07-10
CN106062201B (zh) 2020-11-06
JP2020124200A (ja) 2020-08-20
US20200338131A1 (en) 2020-10-29

Similar Documents

Publication Publication Date Title
CY1122612T1 (el) Μεθοδος
CY1123823T1 (el) Βελτιωμενες συνθεσεις τ κυτταρων
CO2019013609A2 (es) Vectores de neoantígeno de alfavirus
CY1122386T1 (el) Χιμαιρικος υποδοχεας αντιγονων και μεθοδοι χρησης εξ αυτου
CO2017005842A2 (es) Anticuerpos heterodiméricos que se unen a cd3 y cd38
CO2019006541A2 (es) Administración viral de neoantígenos
PE20190563A1 (es) Genes de mini-distrofina optimizados y casetes de expresion y su uso
CO2017011957A2 (es) Variantes de alfa-amilasa y polinucleótidos que codifican las mismas
TWD179056S (zh) 充電器
CO2017001573A2 (es) Receptor quimérico de antígeno anti-cd123
PE20210107A1 (es) Anticuerpos anti-cd3 y metodos de uso
EA202191602A3 (ru) Не содержащая сыворотки среда для культивирования клеток
TWD168670S (zh) 流體匣之部分
CY1124727T1 (el) Πρωτεϊνες συντηξης tatk-cdkl5, συνθεσεις, φαρμακοτεχνικες μορφες και η χρηση αυτων
TWD173184S (zh) 秤
TWD172409S (zh) 電連接器
AR103294A1 (es) Composiciones y procedimientos para la glicosilación de proteínas
TWD166756S (zh) 粉盒
UA104973U (uk) Біологічно активна добавка шумілова
TWD175568S (zh) 雪鏡(一)
TWD171560S (zh) 翹牌器
TWD175126S (zh) 鏡腳
TWD173835S (zh) 髮夾
TWD175566S (zh) 雪鏡
TWD173430S (zh) 圓桶式台車